Harrow announces the successful manufacture of the first of three commercial-scale process performance qualification, PPQ, batches of TRIESENCE 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA-approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. Harrow also announced that the second and third required PPQ batches are now scheduled; and should these PPQ batches meet specifications, the new TRIESENCE production process will be deemed complete, allowing Harrow to relaunch during 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow announces 52-Week data from VEVYE ESSENCE-2 open-label extension study
- Harrow price target raised to $25 from $20 at Lake Street
- Harrow (NASDAQ:HROW) Stock Surges on Successful Product Launch
- Harrow price target raised to $26 from $24 at Craig-Hallum
- Harrow price target raised to $29 from $26 at B. Riley
Questions or Comments about the article? Write to editor@tipranks.com